Megan Mojabi (Flynn)

Cooley advised Oberland Capital, a private investment firm committed to funding innovation across the global healthcare industry, on its agreement to invest up to $600 million in Biohaven (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases.

Cooley advised PetLab Co., a rapidly growing independent pet supplement brand headquartered in London, on its majority stake sale to BC Partners, a top international investment firm.

Cooley advised VectivBio, a clinical-stage biotech company focused on the discovery and development of treatments for severe, rare gastrointestinal (GI) conditions, on its acquisition by Ironwood, with an estimated aggregate consideration of approximately $1 billion.

Cooley advised the shareholders of ICS Learn, an online professional education platform owned by private equity firm Primary Capital Partners, on the platform’s sale to vocational e-learning provider Skill & You, a portfolio company of private equity firm IK Partners. Private equity partner Stephen Rosen led the Cooley team advising the shareholders of ICS Learn.

Cooley advised Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, on its $160 million revenue interest purchase and sale agreement for its investigational product tapinarof and its $40 million senior secured credit facility.